INS and type 2 diabetes mellitus: Further, pharmacogenomic studies have shown that variants in genes associated with insulin secretion and insulin sensitivity, such as KCNQ1, SLC30A8, SLC22A1, TCF7L2 and NOS1AP gene variants, may affect T2DM patients' responsiveness to hypoglycemic drugs [18–21].